|
Clinical pathology in both treatment groups |
|||
| Dimeticone group n (%) |
Permethrin group n (%) |
P value |
|
|
|
|||
| Cervical lymphadenopathy: |
|||
| Before treatment |
49/73 (67.1%) |
54/72 (75.0%) |
P = 0.3 |
| Day 2 |
51/73 (69.9%) |
52/72 (72.2%) |
P = 0.8 |
| Day 4 |
52/73 (71.2%) |
49/72 (68.1%) |
P = 0.7 |
| Day 7 |
39/73 (53.4%) |
46/72 (63.9%) |
P = 0.2 |
| Day 9 |
41/72 (56.9%) |
45/71 (63.4%) |
P = 0.7 |
| Bacterial superinfection of lesions: |
|||
| Before treatment |
1/73 (1.4%) |
0/72 (0%) |
P = 0.3 |
| Day 2 |
1/73 (1.4%) |
1/72 (1.4%) |
P = 1.0 |
| Day 4 |
1/73 (1.4%) |
0/72 (0%) |
P = 0.3 |
| Day 7 |
0/73 (0%) |
0/72 (0%) |
P = 1.0 |
| Day 9 |
0/72 (0%) |
0/71 (0%) |
P = 1.0 |
Heukelbach et al. BMC Infectious Diseases 2008 8:115 doi:10.1186/1471-2334-8-115 |
|||